The effects of the acute administration of the ACE inhibitor ceronapril were studied in 12 Alzheimer's disease (AD) patients and 2 age-matched controls. A 4-week open trial was performed with daily doses of 40-80 mg/day. Testing was performed at baseline and at 4 weeks using the Mini-mental State Exam and the cognitive portion of the Alzheimer's Disease Assessment Scale as cognitive measures, and regional cerebral blood flow (rCBF) as determined by Xe 133 single-photon emission computerized tomography as an indirect measure of brain metabolism. There was no effect on cognition and blood flow increased significantly only in the left temporal region. It was concluded that the acute administration of the ACE inhibitor ceronapril had no significant acute effect on cognitive function or rCBF in AD.
|Original language||English (US)|
|Number of pages||5|
|Journal||Drug Development Research|
|State||Published - Jan 1 1992|
ASJC Scopus subject areas
- Organic Chemistry
- Drug Discovery